VIVUS, Inc. (VVUS) Posts Q1 Loss of 15c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Vivus (VVUS) Revenue/Rx Improving, Needham & Company Notes
May 6, 2014 6:58 AM EDTNeedham & Company analyst Alan Carr weighed in on Vivus (NASDAQ: VVUS) following Q1 results which showed that while Qsymia sales are still low, Revenue/Rx is improving.
Carr comments, "Vivus reported $9.2M in 1Q14 Qsymia sales (+18% q/q), above our $7.5M and... More
